LCM
APGE

Legato Capital Management’s Apogee Therapeutics APGE Stock Holding History

Legato Capital Management’s Portfolio APGE Stock Details APGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-29,968
Closed -$2.52M – 692
2026
Q1 		$2.52M Buy
29,968
+16,417
+121% +$1.19M 0.23% 129
2025
Q4 		$1.02M Buy
+13,551
New +$854K 0.09% 351
2025
Q3 		– Sell
-4,720
Closed -$205K – 565
2025
Q2 		$205K Buy
+4,720
New +$180K 0.02% 519
2024
Q2 		– Sell
-4,792
Closed -$318K – 560
2024
Q1 		$318K Buy
+4,792
New +$209K 0.04% 500

Other funds holding APGE

VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

Legato Capital Management's APGE Position: Q2 2026 in Review

Legato Capital Management sold out of Apogee Therapeutics (APGE) in Q2 2026, closing a stake of 29,968 shares — an estimated $2.52M sold.

Legato Capital Management first reported a position in APGE in Q1 2024 and held it in 4 quarters. The position peaked at $2.52M in Q1 2026. 289 funds tracked by Wall St. Rank hold APGE as of Q2 2026.

  • Legato Capital Management reported no remaining Apogee Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Legato Capital Management sold 29,968 Apogee Therapeutics shares in Q2 2026, an estimated $2.52M.
  • Legato Capital Management first reported a position in Apogee Therapeutics in Q1 2024 and held it in 4 quarters.
  • Legato Capital Management's Apogee Therapeutics position peaked at $2.52M in Q1 2026.
  • 289 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q2 2026.

Based on Legato Capital Management's 13F filing for Q2 2026, filed 6 Aug 2026.